HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA cosmetics adverse reaction monitoring system is "high priority" to agency -- FDA.

This article was originally published in The Rose Sheet

Executive Summary

AHAs, RIO INJURIES "HELPED SHAPE" COSMETIC HOTLINE PLAN, FDA reported in a Sept. 8 letter to House Commerce/Health Subcommittee Chairman Thomas Bliley (R-VA). Written in response to inquiries from Bliley and former Commerce Committee Chairman John Dingell (D-MI), the letter states that "two adverse reaction-related developments helped shape the agency's decision to implement" the cosmetic adverse reaction monitoring initiative -- the increased use of "biologically active ingredients, such as AHAs" in OTC skin care products and the more than 3,000 complaints FDA received regarding Rio hair naturalizers.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel